BRCA2 and ovarian cancer: These tumors also appear to be responsive to platinum-based chemotherapy [22], consistent with what has been shown for breast and ovarian cancer diagnosed in women who carry a germline pathogenic variant in BRCA1 and BRCA2. The identification of a germline pathogenic variant also provides information that is highly relevant to relatives, both men and women, as cascade testing can inform risk management strategies for family members.